MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacep.2021.04.012

Медицинская библиотека · JACC. Clinical electrophysiology · 2021

Incidence of Device-Related Thrombosis in Watchman Patients Undergoing a Genotype-Guided Antithrombotic Strategy.

Della Rocca Domenico G, Horton Rodney P, Di Biase Luigi, Gianni Carola, Trivedi Chintan, Mohanty Sanghamitra, Anannab Alisara, Magnocavallo Michele, Chen Qiong, Tarantino Nicola, Bassiouny Mohamed, Lavalle Carlo, Natale Veronica N, Forleo Giovanni B, Del Prete Armando, Van Niekerk Christoffel Johannes, Al-Ahmad Amin, Burkhardt J David, Gallinghouse G Joseph, Sanchez Javier E, Lakkireddy Dhanunjaya, Gibson Douglas N, Natale Andrea

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to report the incidence of device-related thrombosis (DRT) and thromboembolic (TE) events when an alternative to clopidogrel is prescribed in loss-of-function (LOF) allele carriers of the cytochrome P450 2C19 (CYP2C19) gene.

BACKGROUND

LOF polymorphisms of the CYP2C19 gene are associated with reduced hepatic bioactivation of clopidogrel.

METHODS

A total of 1,002 Watchman patients were included. Six hundred forty-five patients underwent CYP2C19 genetic testing; among patients with clopidogrel resistance, clopidogrel was replaced by either prasugrel (pilot cohort) or half dose direct oral anticoagulant ([DOAC]/Group 1), both in combination with aspirin. We compared the incidence of DRT/TE events among genotyped patients and a control group which received standard dual antiplatelet therapy (DAPT) (Group 2; n = 357). All reported events occurred during a timeframe between 45- and 180-day follow-up transesophageal echocardiograms, when the 2 different antithrombotic strategies (genotype-guided vs standard DAPT) were adopted.

RESULTS

In the pilot cohort (n = 244), bleeding events occurred in 10.2% of patients who received aspirin plus prasugrel, leading to early discontinuation of the prasugrel-based protocol. DOAC Group 1 patients (n = 401), 25.7% were reduced metabolizers, and clopidogrel was replaced by half dose direct oral anticoagulant. DRT was documented in 1 (0.2%) patient of Group 1 and 7 (1.96%) patients of Group 2 (log-rank P = 0.021). The composite endpoint of DRT/TE events was significantly lower among patients receiving a genotype-guided antithrombotic strategy (0.75% vs 3.10%; log-rank P = 0.017).

CONCLUSIONS

In Watchman patients, a genotype-based antithrombotic strategy with aspirin plus half dose DOAC in reduced clopidogrel metabolizers was superior to standard DAPT with respect to DRT/TE events.

Для цитирования: Della Rocca Domenico G, Horton Rodney P, Di Biase Luigi, Gianni Carola, Trivedi Chintan, Mohanty Sanghamitra, Anannab Alisara, Magnocavallo Michele, Chen Qiong, Tarantino Nicola, Bassiouny Mohamed, Lavalle Carlo, Natale Veronica N, Forleo Giovanni B, Del Prete Armando, Van Niekerk Christoffel Johannes, Al-Ahmad Amin, Burkhardt J David, Gallinghouse G Joseph, Sanchez Javier E, Lakkireddy Dhanunjaya, Gibson Douglas N, Natale Andrea. Incidence of Device-Related Thrombosis in Watchman Patients Undergoing a Genotype-Guided Antithrombotic Strategy.. JACC. Clinical electrophysiology. 2021. DOI: 10.1016/j.jacep.2021.04.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.